CDT Equity (NASDAQ:CDT) Shares Down 4.6% – Here’s Why

Posted by Renee Jackson on Nov 22nd, 2025

CDT Equity Inc. (NASDAQ:CDT – Get Free Report) was down 4.6% during mid-day trading on Thursday . The stock traded as low as $1.66 and last traded at $1.66. Approximately 42,168 shares changed hands during mid-day trading, a decline of 30% from the average daily volume of 60,457 shares. The stock had previously closed at $1.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

View Our Latest Stock Report on CDT Equity

CDT Equity Price Performance

The stock’s 50 day simple moving average is $3.93 and its two-hundred day simple moving average is $14.86. The stock has a market cap of $2.69 million, a price-to-earnings ratio of 0.00 and a beta of 1.76.

CDT Equity (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($13.16) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On CDT Equity

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC acquired a new stake in CDT Equity Inc. (NASDAQ:CDT – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned 28.28% of CDT Equity at the end of the most recent quarter. 3.29% of the stock is owned by institutional investors and hedge funds.

CDT Equity Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.